Printer Friendly

BIOTECH FIRM LICENSES MARKETING RIGHTS FOR PERIODONTAL DISEASE ASSAY TO DIVISION OF 3M

 BIOTECH FIRM LICENSES MARKETING RIGHTS
 FOR PERIODONTAL DISEASE ASSAY TO DIVISION OF 3M
 NORWOOD, Mass., Dec. 2 /PRNewswire/ -- Advanced Clinical Technologies, Inc. (ACTech), a Norwood, Mass.-based biotechnology firm, has licensed exclusive U.S. and South American marketing rights for its periodontal disease monitoring assay to 3M Dental Products Division. The assay, developed by ACTech under the name PERIOCHECK Enzyme Activity Test Kit, will be marketed to dentists by 3M as the 3M PERIODONTAL CARE MONITORING SYSTEM.
 The ACTech/3M assay is the only "in vitro" test for monitoring the periodontal health status of patients to be approved for marketing by the U.S. Food & Drug Administration (FDA). Periodontal disease (gum disease) afflicts millions of people and is a major cause of tooth loss in adults. This chairside assay allows the dentist to quickly monitor a patient's disease activity and response to treatment, by measuring specific enzymes that are known to be involved in periodontal tissue destruction.
 ACTech is a privately-held biotechnology firm specializing in oral health care products. 3M Dental Products Division markets a wide range of dental products worldwide, and is based with its parent firm, 3M Company, in St. Paul, Minn.
 -0- 12/2/91
 /CONTACT: Fran Worrall of Spectrum HealthCare Group, Inc. 404-432-8558, for Advanced Clinical Technologies, Inc./ CO: Advanced Clinical Technologies, Inc.; 3M Company ST: Massachusetts IN: MTC SU:


KM -- AT011 -- 1990 12/02/91 16:24 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 2, 1991
Words:233
Previous Article:HADCO CORPORATION REPORTS FISCAL YEAR 1991 PROFITS
Next Article:MICHIGAN TOURISM DOWN SHARPLY
Topics:


Related Articles
Protecting tight bites.
STUDY LINKS INTERLEUKIN TO PERIODONTAL DISEASE
CAMBRIDGE BIOTECH RECEIVES FDA APPROVAL OF PLA FOR IMMUNOASSAY SCREENING TEST TO DETECT HUMAN T CELL LEUKEMIA VIRUS (HTLV-I)
Block Drug Company And Atrix Laboratories Sign Corporate Alliance Agreement
OraPharma Inc. Forms Development Alliance With the University of North Carolina at Chapel Hill.
Enhance Biotech Engages FDA Approval Advisors Ehrreich Consulting.
Enhance Biotech Engages FDA Approval Advisors Ehrreich Consulting; - Ehrreich to support Enhance Biotech as it nears approvals with several of its...
Enhance Biotech Achieves Milestones to Complete $4 Million Funding Arrangement.
ECI Biotech receives small-business grant; $299,066 will aid periodontal work.
Maternal periodontal disease, systemic inflammation, and risk for preeclampsia.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters